Company intelligence / Profile preview

Coram

Ownership: Private
Development stage: Commercial

Overview

Coram is a leading U.S. provider of specialty infusion and nutrition therapy services with over 40 years of experience. The company delivers home-based and ambulatory suite infusions for patients needing complex biologic drugs or nutritional support. As of late 2024/2025, the company has refocused on specialty medications and nutrition therapies after discontinuing most acute home infusion services such as antibiotics. Some regional pharmacy assets were acquired by KabaFusion in 2025.

Therapeutic areas: OtherGastroenterologyImmunology
Modalities: BiologicSmall moleculeNutrition therapy (Total Parenteral Nutrition/Enteral Nutrition)Injectable therapies
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on Coram.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coram.

Explore the full profile